ofloxacin has been researched along with Haemophilus Infections in 29 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Haemophilus Infections: Infections with bacteria of the genus HAEMOPHILUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study assessed daily aspirate samples from an indwelling sinus catheter during high-dose, short-course levofloxacin (750 mg daily x 5 days) treatment of acute maxillary sinusitis." | 9.12 | Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis. ( Ambrose, PG; Anon, JB; Jones, RN; Kahn, JB; Paglia, M; Xiang, J, 2007) |
| "The authors had for aim to evaluate the efficacy and tolerance of oral levofloxacin (500 mg once a day during ten days), as a treatment for acute bacterial sinusitis at risk for complications in adult patients." | 9.11 | [Levofloxacin in the treatment of acute and bacteriologically documented sinusitis with high risk of complications]. ( Gehanno, P; Pessey, JJ; Serrano, E, 2005) |
| "Comparison of efficacy and safety of sparfloxacin vs ofloxacin for treatment of acute bacterial exacerbations of chronic bronchitis (ABECB)." | 9.08 | Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group. ( Bensch, G; Chodosh, S; DeAbate, CA; Harper, L; Henry, D; Jubran, A; Talbot, GH; Tipping, D, 1998) |
| "We describe four patients who had seizures while receiving ofloxacin; no other causes were evident." | 8.79 | Seizures associated with ofloxacin therapy. ( Bonfiglio, MF; Martin, BR; Nackes, NA; Traeger, SM; Wilson, JA, 1995) |
| " An approach to combine ofloxacin with humanized Fab fragments that disrupt biofilms has tremendous potential to quickly resolve chronic otorrhea suffered by children with chronic suppurative otitis media or chronic post-tympanostomy tube otorrhea and thereby improve their quality of life." | 8.02 | Humanized Anti-DNABII Fab Fragments Plus Ofloxacin Eradicated Biofilms in Experimental Otitis Media. ( Bakaletz, LO; Chiang, T; Elmaraghy, CA; Goodman, SD; Novotny, LA, 2021) |
| "The influence of patient relevant parameters such as age, comorbidity, or duration of disease on the treatment success of levofloxacin for community-acquired respiratory tract infections (CARTI) has not been thoroughly elucidated." | 7.72 | The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections. ( Burgmann, H; Kumbein, F; Lukas, A; Mayer, B; Oberbauer, R, 2003) |
| "We describe the first case of failure of oral levofloxacin treatment of community-acquired pneumonia caused by Haemophilus influenzae." | 7.72 | Levofloxacin treatment failure in Haemophilus influenzae pneumonia. ( Alonso-Tarrés, C; Bastida, T; Campos, J; Cortés-Lletget, MC; de la Campa, AG; Pérez-Vázquez, M; Román, F; Tubau, F, 2003) |
| "A murine model of bacteremic Haemophilus influenzae type b pneumonia was used to evaluate the therapeutic efficacies of the quinolone antimicrobial agents enoxacin and ofloxacin compared with those of ampicillin and chloramphenicol." | 7.67 | Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia. ( Borner, K; Kemmerich, B; Pennington, JE, 1987) |
| "This study assessed daily aspirate samples from an indwelling sinus catheter during high-dose, short-course levofloxacin (750 mg daily x 5 days) treatment of acute maxillary sinusitis." | 5.12 | Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis. ( Ambrose, PG; Anon, JB; Jones, RN; Kahn, JB; Paglia, M; Xiang, J, 2007) |
| "The authors had for aim to evaluate the efficacy and tolerance of oral levofloxacin (500 mg once a day during ten days), as a treatment for acute bacterial sinusitis at risk for complications in adult patients." | 5.11 | [Levofloxacin in the treatment of acute and bacteriologically documented sinusitis with high risk of complications]. ( Gehanno, P; Pessey, JJ; Serrano, E, 2005) |
| "Comparison of efficacy and safety of sparfloxacin vs ofloxacin for treatment of acute bacterial exacerbations of chronic bronchitis (ABECB)." | 5.08 | Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group. ( Bensch, G; Chodosh, S; DeAbate, CA; Harper, L; Henry, D; Jubran, A; Talbot, GH; Tipping, D, 1998) |
| "We describe four patients who had seizures while receiving ofloxacin; no other causes were evident." | 4.79 | Seizures associated with ofloxacin therapy. ( Bonfiglio, MF; Martin, BR; Nackes, NA; Traeger, SM; Wilson, JA, 1995) |
| " An approach to combine ofloxacin with humanized Fab fragments that disrupt biofilms has tremendous potential to quickly resolve chronic otorrhea suffered by children with chronic suppurative otitis media or chronic post-tympanostomy tube otorrhea and thereby improve their quality of life." | 4.02 | Humanized Anti-DNABII Fab Fragments Plus Ofloxacin Eradicated Biofilms in Experimental Otitis Media. ( Bakaletz, LO; Chiang, T; Elmaraghy, CA; Goodman, SD; Novotny, LA, 2021) |
| "This paper reports the first case of Haemophilus quentini bacteremia with reduced susceptibility to levofloxacin and resistance to nalidixic acid identified by 16S rRNA sequencing." | 3.73 | Reduced levofloxacin susceptibility and tetracycline resistance in a clinical isolate of Haemophilus quentini identified by 16S rRNA sequencing. ( Ho, PL; Lau, SK; Mak, GC; Tse, CW; Wong, SS, 2005) |
| "The influence of patient relevant parameters such as age, comorbidity, or duration of disease on the treatment success of levofloxacin for community-acquired respiratory tract infections (CARTI) has not been thoroughly elucidated." | 3.72 | The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections. ( Burgmann, H; Kumbein, F; Lukas, A; Mayer, B; Oberbauer, R, 2003) |
| "We describe the first case of failure of oral levofloxacin treatment of community-acquired pneumonia caused by Haemophilus influenzae." | 3.72 | Levofloxacin treatment failure in Haemophilus influenzae pneumonia. ( Alonso-Tarrés, C; Bastida, T; Campos, J; Cortés-Lletget, MC; de la Campa, AG; Pérez-Vázquez, M; Román, F; Tubau, F, 2003) |
| "A murine model of bacteremic Haemophilus influenzae type b pneumonia was used to evaluate the therapeutic efficacies of the quinolone antimicrobial agents enoxacin and ofloxacin compared with those of ampicillin and chloramphenicol." | 3.67 | Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia. ( Borner, K; Kemmerich, B; Pennington, JE, 1987) |
| "This study aimed to explore the pharmacokinetic features of levofloxacin (LVFX) in Chinese patients with infections and to confirm oral LVFX 500 mg once daily as an optimal treatment regimen based on pharmacokinetic-pharmacodynamic (PK-PD) analysis." | 2.74 | Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. ( Cao, GY; Huang, JA; Liu, YB; Shi, YG; Si, B; Sun, SH; Wu, XJ; Xia, QM; Xiao, ZK; Xu, JF; Zhang, J; Zhang, YY, 2009) |
| "In immunocompetent patients, septic arthritis of the acromioclavicular (AC) joint is a rare entity." | 1.36 | Acromioclavicular septic arthritis: a case report of a novel pathogen. ( Abell, BE; Carey, TW; Jackson, K; Roure, R, 2010) |
| "Levofloxacin resistance was detected in 2 of 2,834 isolates (0." | 1.32 | Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. ( Critchley, IA; Evangelista, AT; Jones, ME; Karlowsky, JA; Noel, GJ; Sahm, DF; Thornsberry, C, 2003) |
| "HSR-903 was active against experimental respiratory tract infections in mice challenged with penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae and Haemophilus influenzae strains." | 1.30 | In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. ( Domon, H; Miyazaki, S; Yamaguchi, K; Yoshizumi, S, 1998) |
| "Ciprofloxacin and ofloxacin were the most active agents, (MIC90 0." | 1.28 | In vitro activity of 9 antimicrobial agents against 177 strains of Haemophilus influenzae isolated from hospitalized patients. ( Lingaas, E; Teigen, K, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (13.79) | 18.7374 |
| 1990's | 5 (17.24) | 18.2507 |
| 2000's | 16 (55.17) | 29.6817 |
| 2010's | 3 (10.34) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Novotny, LA | 1 |
| Chiang, T | 1 |
| Goodman, SD | 1 |
| Elmaraghy, CA | 1 |
| Bakaletz, LO | 1 |
| Tanaseanu, C | 1 |
| Bergallo, C | 1 |
| Teglia, O | 1 |
| Jasovich, A | 1 |
| Oliva, ME | 1 |
| Dukart, G | 1 |
| Dartois, N | 1 |
| Cooper, CA | 1 |
| Gandjini, H | 1 |
| Mallick, R | 1 |
| Zhang, J | 1 |
| Xu, JF | 1 |
| Liu, YB | 1 |
| Xiao, ZK | 1 |
| Huang, JA | 1 |
| Si, B | 1 |
| Sun, SH | 1 |
| Xia, QM | 1 |
| Wu, XJ | 1 |
| Cao, GY | 1 |
| Shi, YG | 1 |
| Zhang, YY | 1 |
| Carey, TW | 1 |
| Jackson, K | 1 |
| Roure, R | 1 |
| Abell, BE | 1 |
| Lorenzo Garde, L | 1 |
| Bolaños Rivero, M | 1 |
| Turégano García, Á | 1 |
| Martín Sánchez, AM | 1 |
| Beauchamp, ME | 1 |
| Powari, M | 1 |
| Smith, ME | 1 |
| Pessey, JJ | 2 |
| Almeda, FQ | 1 |
| Tenorio, AR | 1 |
| Barkatullah, S | 1 |
| Parrillo, JE | 1 |
| Simon, DM | 1 |
| Karlowsky, JA | 1 |
| Thornsberry, C | 1 |
| Critchley, IA | 1 |
| Jones, ME | 1 |
| Evangelista, AT | 1 |
| Noel, GJ | 1 |
| Sahm, DF | 1 |
| Burgmann, H | 1 |
| Mayer, B | 1 |
| Lukas, A | 1 |
| Kumbein, F | 1 |
| Oberbauer, R | 1 |
| Bastida, T | 1 |
| Pérez-Vázquez, M | 2 |
| Campos, J | 2 |
| Cortés-Lletget, MC | 1 |
| Román, F | 2 |
| Tubau, F | 1 |
| de la Campa, AG | 1 |
| Alonso-Tarrés, C | 1 |
| Aracil, B | 1 |
| Cantón, R | 1 |
| Nazir, J | 1 |
| Urban, C | 1 |
| Mariano, N | 1 |
| Burns, J | 1 |
| Tommasulo, B | 1 |
| Rosenberg, C | 1 |
| Segal-Maurer, S | 1 |
| Rahal, JJ | 1 |
| Gehanno, P | 1 |
| Serrano, E | 1 |
| Mak, GC | 2 |
| Ho, PL | 2 |
| Tse, CW | 2 |
| Lau, SK | 1 |
| Wong, SS | 1 |
| Chow, KH | 1 |
| Cheung, CH | 1 |
| Qin, L | 1 |
| Watanabe, H | 1 |
| Asoh, N | 1 |
| Watanabe, K | 1 |
| Oishi, K | 1 |
| Mizota, T | 1 |
| Nagatake, T | 1 |
| Anon, JB | 1 |
| Paglia, M | 1 |
| Xiang, J | 1 |
| Ambrose, PG | 1 |
| Jones, RN | 1 |
| Kahn, JB | 1 |
| Liskova, A | 1 |
| Benca, J | 1 |
| Kalavsky, E | 1 |
| Kovac, M | 1 |
| Rudinsky, B | 1 |
| Ondrusova, A | 1 |
| Kiwou, M | 1 |
| Kobayashi, H | 1 |
| Takamura, K | 1 |
| Kono, K | 1 |
| Onodera, S | 1 |
| Sasaki, N | 1 |
| Nagahama, F | 1 |
| Kawakami, Y | 1 |
| Honma, Y | 1 |
| Matsuzaki, M | 1 |
| Tanimura, K | 1 |
| Traeger, SM | 1 |
| Bonfiglio, MF | 1 |
| Wilson, JA | 1 |
| Martin, BR | 1 |
| Nackes, NA | 1 |
| Yoshizumi, S | 1 |
| Domon, H | 1 |
| Miyazaki, S | 1 |
| Yamaguchi, K | 1 |
| DeAbate, CA | 1 |
| Henry, D | 1 |
| Bensch, G | 1 |
| Jubran, A | 1 |
| Chodosh, S | 1 |
| Harper, L | 1 |
| Tipping, D | 1 |
| Talbot, GH | 1 |
| Vila, J | 1 |
| Ruiz, J | 1 |
| Sanchez, F | 1 |
| Navarro, F | 1 |
| Mirelis, B | 1 |
| de Anta, MT | 1 |
| Prats, G | 1 |
| Shah, PM | 1 |
| Teigen, K | 1 |
| Lingaas, E | 1 |
| Davies, BI | 1 |
| Maesen, FP | 1 |
| Teengs, JP | 1 |
| Baur, C | 1 |
| Quentin, R | 1 |
| Koubaa, N | 1 |
| Cattier, B | 1 |
| Gavignet, M | 1 |
| Goudeau, A | 1 |
| Kemmerich, B | 1 |
| Borner, K | 1 |
| Pennington, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia[NCT00079885] | Phase 3 | 430 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Intravenous Tigecycline Vs Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia[NCT00081575] | Phase 3 | 434 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| An Open-label, Multi-center, Non-comparative Sinus Puncture Study of 750 mg, Short-course Levofloxacin in the Treatment of Acute Maxillary Sinusitis[NCT00236652] | Phase 3 | 18 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for ofloxacin and Haemophilus Infections
| Article | Year |
|---|---|
[Update on levofloxacin in the management of acute sinusitis with risk of complications].
Topics: Abscess; Acute Disease; Anti-Infective Agents; Cellulitis; Clinical Trials as Topic; Disease Progres | 2002 |
Seizures associated with ofloxacin therapy.
Topics: Aged; Aged, 80 and over; Female; Haemophilus Infections; Haemophilus influenzae; Humans; Klebsiella | 1995 |
The use of levofloxacin in the treatment of respiratory tract infection.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infections; Haemophilus Infec | 2000 |
7 trials available for ofloxacin and Haemophilus Infections
| Article | Year |
|---|---|
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bronchitis, Chronic; China; Co | 2009 |
[Levofloxacin in the treatment of acute and bacteriologically documented sinusitis with high risk of complications].
Topics: Acute Disease; Adolescent; Adult; Africa, Southern; Aged; Bacterial Infections; Female; France; Haem | 2005 |
Short report: antimicrobial susceptibility and genetic characteristics of Haemophilus influenzae isolated from patients with respiratory tract infections between 1987 and 2000, including beta-lactamase-negative ampicillin-resistant strains.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactam Resistance; Ceftriaxone; Female; Haemophilus Infectio | 2007 |
Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Catheters, Indwelling; Dose-Response Relationship, Drug | 2007 |
[Comparison of DL-8280 and amoxicillin in the treatment of respiratory tract infections].
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bronchiectasis; Bronchitis; Clinical Trials as Topi | 1984 |
Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Chlamy | 1998 |
19 other studies available for ofloxacin and Haemophilus Infections
| Article | Year |
|---|---|
Humanized Anti-DNABII Fab Fragments Plus Ofloxacin Eradicated Biofilms in Experimental Otitis Media.
Topics: Animals; Biofilms; Chinchilla; DNA-Binding Proteins; DNA, Bacterial; Haemophilus Infections; Haemoph | 2021 |
Acromioclavicular septic arthritis: a case report of a novel pathogen.
Topics: Acromioclavicular Joint; Aged; Anti-Bacterial Agents; Arthritis, Infectious; Debridement; Female; Ha | 2010 |
[Intraperitoneal abscess for Eikenella corrodens].
Topics: Abdominal Abscess; Adenocarcinoma; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacteri | 2011 |
An unusual tracheal polyp: a case report.
Topics: Aged; Anti-Bacterial Agents; Diagnosis, Differential; Female; Haemophilus Infections; Haemophilus in | 2012 |
Infective endocarditis due to Haemophilus aphrophilus treated with levofloxacin.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Echocardiography, Transesophageal; E | 2002 |
Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Azithromycin; Child; Child, Preschool; Drug Resistan | 2003 |
The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Child; Child, Preschool; Chlamydo | 2003 |
Levofloxacin treatment failure in Haemophilus influenzae pneumonia.
Topics: Aged; Anti-Infective Agents; Community-Acquired Infections; DNA Gyrase; Electrophoresis, Gel, Pulsed | 2003 |
Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations.
Topics: Aza Compounds; Base Sequence; Ciprofloxacin; DNA Gyrase; DNA Primers; DNA Topoisomerase IV; Fluoroqu | 2004 |
Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology.
Topics: Age Factors; Anti-Infective Agents; Case-Control Studies; DNA, Bacterial; Drug Resistance, Bacterial | 2004 |
Reduced levofloxacin susceptibility and tetracycline resistance in a clinical isolate of Haemophilus quentini identified by 16S rRNA sequencing.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Typing Techniques; DNA, Bacterial; Drug Resistance, Mul | 2005 |
Invasive Haemophilus influenzae isolates with decreased levofloxacin susceptibility in Hong Kong.
Topics: Anti-Bacterial Agents; Haemophilus Infections; Haemophilus influenzae; Hong Kong; Humans; Levofloxac | 2006 |
Antimicrobial susceptibility of cerebrospinal isolates from patients with meningitis.
Topics: Anti-Bacterial Agents; Cefotaxime; Chloramphenicol; Drug Resistance, Microbial; Haemophilus Infectio | 2007 |
In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Fluoroquinolones; Haemophilus Infections; Haemophi | 1998 |
Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin.
Topics: Amino Acid Substitution; Anti-Infective Agents; DNA Topoisomerase IV; DNA Topoisomerases, Type II; F | 1999 |
In vitro activity of 9 antimicrobial agents against 177 strains of Haemophilus influenzae isolated from hospitalized patients.
Topics: Aztreonam; beta-Lactamases; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microb | 1990 |
[New oral quinolone compounds in chronic bronchitis].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Cipr | 1986 |
In vitro activities of five new quinolones against 88 genital and neonatal Haemophilus isolates.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Enoxacin; Female; Genital Diseases, Female; Genital Diseases, | 1988 |
Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Chloramphenicol; Enoxacin; Female; Haemophilus Infection | 1987 |